TW202400601A - 作為parp抑製劑的取代的三環類化合物及其用途 - Google Patents

作為parp抑製劑的取代的三環類化合物及其用途 Download PDF

Info

Publication number
TW202400601A
TW202400601A TW112107292A TW112107292A TW202400601A TW 202400601 A TW202400601 A TW 202400601A TW 112107292 A TW112107292 A TW 112107292A TW 112107292 A TW112107292 A TW 112107292A TW 202400601 A TW202400601 A TW 202400601A
Authority
TW
Taiwan
Prior art keywords
methyl
piperazin
group
optionally substituted
fluoro
Prior art date
Application number
TW112107292A
Other languages
English (en)
Chinese (zh)
Inventor
遂雄 蔡
野 田
王曉珠
張樂天
Original Assignee
大陸商上海瑛派藥業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海瑛派藥業有限公司 filed Critical 大陸商上海瑛派藥業有限公司
Publication of TW202400601A publication Critical patent/TW202400601A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112107292A 2022-03-11 2023-03-01 作為parp抑製劑的取代的三環類化合物及其用途 TW202400601A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202210260944 2022-03-11
CN2022102609447 2022-03-11
CN2022104488038 2022-04-24
CN202210448803 2022-04-24
CN202211219599 2022-09-30
CN2022112195999 2022-09-30
CN2022115059040 2022-11-28
CN202211505904 2022-11-28

Publications (1)

Publication Number Publication Date
TW202400601A true TW202400601A (zh) 2024-01-01

Family

ID=87937164

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107292A TW202400601A (zh) 2022-03-11 2023-03-01 作為parp抑製劑的取代的三環類化合物及其用途

Country Status (11)

Country Link
US (1) US20250215013A1 (cg-RX-API-DMAC7.html)
EP (1) EP4490161A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508122A (cg-RX-API-DMAC7.html)
KR (1) KR20240162104A (cg-RX-API-DMAC7.html)
CN (1) CN119013279A (cg-RX-API-DMAC7.html)
AU (1) AU2023229992A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253468A1 (cg-RX-API-DMAC7.html)
IL (1) IL315586A (cg-RX-API-DMAC7.html)
MX (1) MX2024011086A (cg-RX-API-DMAC7.html)
TW (1) TW202400601A (cg-RX-API-DMAC7.html)
WO (1) WO2023169226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof
JP2026507185A (ja) * 2023-03-01 2026-02-27 インパクト セラピューティクス (シャンハイ), インコーポレイテッド Parp阻害剤としての置換窒素含有三環式化合物及びその使用
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途
TW202525808A (zh) * 2023-09-13 2025-07-01 大陸商上海瑛派藥業有限公司 用作parp1抑制劑的化合物、其用途及包含其之組合物
WO2026142998A1 (en) * 2024-12-24 2026-07-02 Gilead Sciences, Inc. Crystalline forms of a parp1 inhibitor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
MX2009007053A (es) * 2006-12-28 2009-07-09 Abbott Lab Inhibidores de poli (adp-ribosa) polimerasa.
EP2389379A1 (en) * 2009-01-23 2011-11-30 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
US8541417B2 (en) * 2009-07-30 2013-09-24 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
PT3312177T (pt) * 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
AU2022334408A1 (en) * 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023122140A1 (en) * 2021-12-22 2023-06-29 Synnovation Therapeutics, Inc. Parp1 inhibitors
US20250221987A1 (en) * 2022-01-13 2025-07-10 Acerand Therapeutics (Hong Kong) Limited Piperazino ring-containing derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof
PT4497438T (pt) * 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
EP4524142A4 (en) * 2022-05-07 2026-07-01 Scibrunch Therapeutics Co Ltd FLUOROQUINOXALINONE DERIVATIVE FOR THE SELECTIVE INHIBITION OF PARP1
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
AU2023378452A1 (en) * 2022-11-10 2025-06-19 Haihe Biopharma Co., Ltd. Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
MX2024011086A (es) 2024-12-06
JP2025508122A (ja) 2025-03-21
EP4490161A1 (en) 2025-01-15
WO2023169226A1 (en) 2023-09-14
KR20240162104A (ko) 2024-11-14
CN119013279A (zh) 2024-11-22
EP4490161A4 (en) 2026-03-11
CA3253468A1 (en) 2023-09-14
US20250215013A1 (en) 2025-07-03
AU2023229992A1 (en) 2024-10-10
IL315586A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7605486B2 (ja) キナーゼ阻害剤としての置換された縮合複素芳香族二環式化合物およびその使用
IL311024A (en) Substituted tricyclic compounds as parp inhibitors and use thereof
CN102015705B (zh) 稠合的杂环衍生物及其用途
KR20240162104A (ko) Parp 억제제로서의 치환된 트리시클릭 화합물 및 이의 용도
BRPI0708615A2 (pt) compostos de pirazol heterobicìclicos e métodos de uso
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
JP2024540921A (ja) Usp1阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用
CN116783181B (zh) 取代的稠合双环类化合物作为parp抑制剂及其应用
CN116670134A (zh) 取代的咪唑并[1,5-b]哒嗪化合物作为激酶抑制剂及其应用
CN121925419A (zh) 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
HK40115331A (en) Substituted tricyclic compounds as parp inhibitors and the use thereof
WO2024179547A1 (en) Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof
HK40104162A (en) Substituted tricyclic compounds as parp inhibitors and use thereof
HK40070099B (en) Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof
HK40070099A (en) Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof
EA049140B1 (ru) Замещенные конденсированные гетероароматические бициклические соединения в качестве ингибиторов киназ и их применение
CN103467481A (zh) 二氢吡啶类化合物、其组合物、制备方法和用途
HK40086646B (en) Pyrazole compound and preparation method therefor and use thereof